Atrial fibrillation and heart failure with preserved ejection fraction: diagnostic challenges and therapeutic opportunities

Heart failure with preserved ejection fraction (HFpEF) is a syndrome characterised by cardiac and non-cardiac physiologic disturbances, commonly underpinned by cardiometabolic abnormalities, which culminate in elevated left ventricular filling pressures and progressive symptoms of exercise intolerance. Arrhythmias, particularly atrial fibrillation (AF), are common in HFpEF and have important clinical implications. AF complicates the diagnosis and management of HFpEF. In this review, we synthesise the impact of AF on disease detection, symptom burden and prognosis and HFpEF treatment. Furthermore, we review pharmacological and interventional therapies that may mitigate the risk of AF and improve how patients with HFpEF feel, function and survive.

Authors

Institutions

Publication Details

Journal
Heart
Published
2026-02-05
DOI
https://doi.org/10.1136/heartjnl-2025-326954
Citations
1
Primary Topic
Cardiovascular Function and Risk Factors
Type
article
Field-Weighted Citation Impact
30.07
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Atrial fibrillation and heart failure with preserved ejection fraction: diagnostic challenges and therapeutic opportunities

Faro R. Verelst, Andreas B. Gevaert, Harriette G C van Spall, F Z Ahmed et al.
1 citations
Heart
Cardiovascular Function and Risk Factors
30.07
article

Atrial fibrillation and heart failure with preserved ejection fraction: diagnostic challenges and therapeutic opportunities

Faro R. Verelst, Andreas B. Gevaert, Harriette G C van Spall, F Z Ahmed, Klaus K Witte
article en
1 citations

Abstract

Heart failure with preserved ejection fraction (HFpEF) is a syndrome characterised by cardiac and non-cardiac physiologic disturbances, commonly underpinned by cardiometabolic abnormalities, which culminate in elevated left ventricular filling pressures and progressive symptoms of exercise intolerance. Arrhythmias, particularly atrial fibrillation (AF), are common in HFpEF and have important clinical implications. AF complicates the diagnosis and management of HFpEF. In this review, we synthesise the impact of AF on disease detection, symptom burden and prognosis and HFpEF treatment. Furthermore, we review pharmacological and interventional therapies that may mitigate the risk of AF and improve how patients with HFpEF feel, function and survive.

Heart
University of Antwerp (BE), Leeds Teaching Hospitals NHS Trust (GB), Queen Elizabeth II Health Sciences Centre (CA), Population Health Research Institute (CA), Clinical Research Institute (US), Antwerp University Hospital (BE), Baim Institute for Clinical Research (US), Duke Medical Center (US), Impact (CA), Keele University (GB), McMaster University (CA)
Good health and well-being
Openalex Percentile: Top 1%
Cardiovascular Function and Risk Factors
30.07
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Atrial fibrillation and heart failure with preserved ejection fraction: diagnostic challenges and therapeutic opportunities — Faro R. Verelst, Andreas B. Gevaert, et al. · Heart (2026) | TGRS Research Map | TGRS